GERM ETFMG Treatments Testing and Advancements ETF

Seeks to track, before fees and expenses, the Prime Treatments, Testing and Advancements Index.The Index is designed to track both event-driven news and long-term trends of companies engaged in developing treatments and vaccines, or diagnostic technology, in the fight against infectious diseases. Eligible companies are U.S. exchange traded companies that are engaged in Treatments, Testing, and/or Advancements Focused Business, which is defined as i) performing research, development, and commercialization of treatments or vaccines for infectious diseases, or ii) the research, development, manufacturing, and provision of biological tests for patients. Prime Indexes determines whether a company is eligible based on the assessment of: i) if a company has one or more vaccines or treatments for infectious diseases in preclinical research, in any phase of U.S. Food and Drug Administration (“FDA”) clinical trials, or in commercial stage and is classified by North American Industry Classification System as either a) “Pharmaceutical and Medicine Manufacturing”, or b) “Research and Development in the Physical, Engineering, and Life Sciences”; or ii) if a company derives more than 50% of its revenue from research, development, manufacturing, and provision of biological tests for patients.

$43.38  -0.06 (-0.15%)
As of 09/22/2021 16:00:00 EST     IEX book   CBOE book


ETF Information
Sponsor:     ETF Managers Group
Category1:  US Equity
Category2:  Single industry
Category3:  Healthcare
Morningstar category:  
Leverage factor:  1.00
Inception date:  06/16/2020
Index tracking method: Passive replication
Current yield:  0.78%
Historical average yield:  0.78%
Market cap:  $68,448,000
Average volume:  16,920
Fees:     0.6800%

Index Information
Prime Treatments, Testing and Advancements Index
Index symbol:  PGERMP
Provider:   Prime Indexes
Index weighting:   Market capitalization
Index inception date:  06/08/2020
Backtesting data exists:   No
Number of holdings:  56  (as of 06/17/2020)
Rebalanced:  Quarterly
Reconstituted:  Quarterly

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy